NCT00657202 Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 Status COMPLETED Phase EARLY_PHASE1
NCT00644280 Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery Status TERMINATED Phase NA
NCT00640640 The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD) Status UNKNOWN Phase NA
NCT00637377 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) Status COMPLETED Phase PHASE3
NCT00606138 Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging Status COMPLETED Phase PHASE1/PHASE2
NCT00599222 The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study Status COMPLETED Phase PHASE3
NCT00593450 Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial Status COMPLETED Phase PHASE3
NCT00590694 Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments Status COMPLETED Phase PHASE2/PHASE3
NCT00567697 A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO Status COMPLETED Phase PHASE3
NCT00562406 Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES) Status COMPLETED Phase NA
NCT00561834 Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy Status COMPLETED Phase PHASE1
NCT00559715 Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab Status UNKNOWN Phase PHASE3
NCT00557791 Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON) Status WITHDRAWN Phase PHASE3
NCT00540930 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Status UNKNOWN Phase PHASE4
NCT00539734 Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration Status COMPLETED Phase NA
NCT00533520 Evaluation of Dosing Interval of Higher Doses of Ranibizumab Status COMPLETED Phase PHASE4